Horizon Pharma traded at $109.68 this Friday February 3rd, decreasing $0.11 or 0.10 percent since the previous trading session. Looking back, over the last four weeks, Horizon Pharma lost 3.35 percent. Over the last 12 months, its price rose by 18.51 percent. Looking ahead, we forecast Horizon Pharma to be priced at 105.96 by the end of this quarter and at 93.10 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
109.68
Daily Change
-0.10%
Yearly
18.51%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Takeda 4,171.00 117.00 2.89% 23.26%
AbbVie 145.20 0.36 0.25% 3.24%
ALKERMES 27.35 -0.27 -0.98% 15.35%
Amgen 245.17 -1.36 -0.55% 10.38%
AstraZeneca 10,540.90 290.90 2.84% 27.27%
Bristol-Myers Squibb 74.45 1.68 2.31% 14.56%
Cara Therapeutics 12.26 0.31 2.59% 15.01%
Coherus Biosciences 8.49 -0.47 -5.25% -31.09%
Endo International 0.10 -0.001 -0.72% -96.89%
Horizon Pharma 109.68 -0.11 -0.10% 18.51%
Jazz Pharmaceuticals 155.64 -0.76 -0.49% 10.43%
Eli Lilly 339.08 8.38 2.53% 39.96%
Merck & Co 102.94 -0.52 -0.50% 31.03%
Novartis 79.63 1.37 1.75% -0.26%
Prestige Brands 60.96 0.61 1.01% 4.51%
Pacira 41.86 -1.21 -2.81% -34.96%
Pfizer 44.06 -0.28 -0.63% -16.87%
Perrigo 37.20 0.15 0.40% 1.39%
Revance Therapeutics 34.92 -0.35 -0.99% 161.38%
Supernus Pharmaceuticals 41.61 -0.42 -1.00% 34.53%
Teva Pharmaceutical Industries 10.76 0.05 0.47% 26.44%
Bausch Health Companies Inc 10.53 0.01 0.10% -66.33%
Xeris Pharmaceuticals Inc 1.18 -0.08 -6.35% -45.12%
Zoetis 167.80 -3.20 -1.87% -15.91%

Indexes Price Day Year
USND 12007 -193.86 -1.59% -14.83%
US2000 1986 -15.69 -0.78% -0.84%

Horizon Pharma
Horizon Therapeutics plc is a biotechnology company that is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare, autoimmune and serious inflammatory diseases. The Company's portfolio is composed of approximately 12 medicines in the areas of rare diseases, gout, ophthalmology and inflammation. The Company has two reportable segments: the orphan and the inflammation segment. The orphan segment includes the medicines TEPEZZA, KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, UPLIZNA and also the Company’s research and development (R&D) programs. TEPEZZA is a monoclonal antibody and a targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R). KRYSTEXXA is an infused medicine for uncontrolled gout. The Company's other orphan segment medicines, RAVICTI, PROCYSBI and ACTIMMUNE, treats serious chronic diseases. The inflammation segment includes PENNSAID 2%, DUEXIS, RAYOS and VIMOVO medicines.